EUVIMEDEUVIMED entdecken
Open Access

Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data

Jeffrey A Scott iD, Jochen Lennerz iD, Melissa Lynne Johnson iD, Lucio N Gordan, Robert H Dumanois iD, Luca Quagliata iD, Lauren L Ritterhouse iD, Federico Cappuzzo iD, Brandon Wang, Mei Xue, Anupama Vasudevan, Prateesh Varughese und 5 weitere

JCO Oncology Practice · 2024

DOI: 10.1200/op.22.00611 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2024. Verfasst von Jeffrey A Scott und 16 weiteren Autor:innen. Beteiligte Einrichtung: Integra Connect, West Palm Beach, FL. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Identification and targeting of actionable oncogenic drivers (AODs) in advanced non–small-cell lung cancer (NSCLC) has dramatically improved outcomes. However, genomic testing uptake is variable and hampered by factors including slow turnaround time, frequently resulting in initial non–tyrosine kinase inhibitor (TKI) treatment. We investigate how this behavior affects outcomes. METHODS This retrospective analysis of real-world, deidentified data from the Integra Connect Database included adults with stage IV NSCLC newly diagnosed from January 1, 2018, to December 31, 2020, with mutations of EGFR, ALK, ROS1, BRAF, MET, RET, ERBB2, or NTRK. Outcomes were reported as time to next treatment or death (TTNT) and overall survival (OS). RESULTS Five hundred ten patients harboring AODs were identified and grouped as follows: group A (n = 379) were treated after the AOD was reported and served as the comparator. One hundred thirty-one patients treated before their AOD report were divided into group B (n = 47) who were initially started on chemotherapy and/or checkpoint inhibitor but switched to appropriate TKI within 35 days and group C (n = 84) who were also started empirically on non-TKI and did not switch within 35 days. Survival (OS) was significantly superior in group A compared with group C; TTNT was significantly superior in group A compared with groups B and C. CONCLUSION For patients harboring AODs in advanced NSCLC, initial treatment before receipt of genomic test results yields significantly inferior outcomes and should be avoided. Molecular profiling panels with rapid turnaround times are essential to optimize patient outcomes and should be standard of care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAdultHumansTyrosine Kinase InhibitorsRetrospective StudiesProtein-Tyrosine KinasesProto-Oncogene ProteinsMutation

Substanzen

Tyrosine Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene Proteins

Autor:innen und Institutionen

  • Integra Connect, West Palm Beach, FL.
  • Massachusetts General Hospital/Harvard Medical School, Boston, MA.
  • Lung Cancer Research, Sarah Cannon Research Institute, Nashville, TN.
  • Research Institute, Florida Cancer Specialists, Fort Myers, FL.
  • Thermo Fisher Scientific, Waltham, MA.
  • Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Roma, Italy.

ORCID-Profile: Jeffrey A Scott, Jochen Lennerz, Melissa Lynne Johnson, Robert H Dumanois, Luca Quagliata, Lauren L Ritterhouse, Federico Cappuzzo, Hinco J Gierman

Zitieren

APA

Scott, J. A., Lennerz, J., Johnson, M. L., Gordan, L. N., Dumanois, R. H., Quagliata, L., Ritterhouse, L. L., Cappuzzo, F., Wang, B., Xue, M., Vasudevan, A., Varughese, P., Vaidya, V., Gart, M., Dorrow, N., Gierman, H. J., & Choksi, R. J. (2024). Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data. JCO Oncology Practice. https://doi.org/10.1200/op.22.00611

Vancouver

Scott JA, Lennerz J, Johnson ML, Gordan LN, Dumanois RH, Quagliata L, et al. Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data. JCO Oncology Practice. 2024. doi:10.1200/op.22.00611

BibTeX
@article{Scott2024,
  author = {Scott, Jeffrey A and Lennerz, Jochen and Johnson, Melissa Lynne and Gordan, Lucio N and Dumanois, Robert H and Quagliata, Luca and Ritterhouse, Lauren L and Cappuzzo, Federico and Wang, Brandon and Xue, Mei and Vasudevan, Anupama and Varughese, Prateesh and Vaidya, Varun and Gart, Mike and Dorrow, Natalie and Gierman, Hinco J and Choksi, Rushir J},
  title = {Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data},
  journal = {JCO Oncology Practice},
  year = {2024},
  doi = {10.1200/op.22.00611}
}
Kostenlos starten →